Cargando…

Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study

Immediate breast reconstruction after mastectomy combined with chemotherapy is the preferred option for patients with early-stage breast cancer who require both superior clinical and aesthetic outcomes. The present study aimed to determine the survival benefits of neoadjuvant and adjuvant chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chia-Hua, Yang, Jie-Ru, Tsai, I-Chen, Hsu, Chiann-Yi, Yean, Lum Chih, Hung, Chih-Chiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641822/
https://www.ncbi.nlm.nih.gov/pubmed/36420073
http://dx.doi.org/10.3892/ol.2022.13557
_version_ 1784826167374643200
author Liu, Chia-Hua
Yang, Jie-Ru
Tsai, I-Chen
Hsu, Chiann-Yi
Yean, Lum Chih
Hung, Chih-Chiang
author_facet Liu, Chia-Hua
Yang, Jie-Ru
Tsai, I-Chen
Hsu, Chiann-Yi
Yean, Lum Chih
Hung, Chih-Chiang
author_sort Liu, Chia-Hua
collection PubMed
description Immediate breast reconstruction after mastectomy combined with chemotherapy is the preferred option for patients with early-stage breast cancer who require both superior clinical and aesthetic outcomes. The present study aimed to determine the survival benefits of neoadjuvant and adjuvant chemotherapy for patients with early-stage breast cancer who have undergone immediate breast reconstruction after mastectomy in Taiwan. The present study compared overall survival (OS) following neoadjuvant or adjuvant chemotherapy in 139 patients with early-stage breast cancer who underwent immediate breast reconstruction after mastectomy. Patient data were used retrospectively as an unmatched cohort. Next, 37 neoadjuvant cases were matched with 37 adjuvant controls through 1:1 age-, clinical stage-, and molecular subtype-matching. OS differences between the cases and controls were determined using Kaplan-Meier survival curve analyses. Here, 77.7 and 81.1% of the unmatched and matched cohort patients were aged <50 years, respectively. Of the matched neoadjuvant cases, 10 (15.6%) reached pathologic complete response after neoadjuvant chemotherapy, whereas 5 (13.5%) neoadjuvant cases succumbed during the study period. The neoadjuvant matched cases demonstrated a significantly poor OS with their adjuvant matched controls (P=0.044); nevertheless, the stratification analysis results demonstrated that the survival differences between the neoadjuvant and the adjuvant controls decreased after matching. Targeted therapy demonstrated the same OS benefits for both the neoadjuvant matched cases and adjuvant matched controls (P=1.000). This study provided matched case-control evidence for the feasibility of neoadjuvant chemotherapy combined with targeted therapy for patients with early-stage breast cancer with immediate breast reconstruction after mastectomy in a Taiwanese female population.
format Online
Article
Text
id pubmed-9641822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-96418222022-11-22 Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study Liu, Chia-Hua Yang, Jie-Ru Tsai, I-Chen Hsu, Chiann-Yi Yean, Lum Chih Hung, Chih-Chiang Oncol Lett Articles Immediate breast reconstruction after mastectomy combined with chemotherapy is the preferred option for patients with early-stage breast cancer who require both superior clinical and aesthetic outcomes. The present study aimed to determine the survival benefits of neoadjuvant and adjuvant chemotherapy for patients with early-stage breast cancer who have undergone immediate breast reconstruction after mastectomy in Taiwan. The present study compared overall survival (OS) following neoadjuvant or adjuvant chemotherapy in 139 patients with early-stage breast cancer who underwent immediate breast reconstruction after mastectomy. Patient data were used retrospectively as an unmatched cohort. Next, 37 neoadjuvant cases were matched with 37 adjuvant controls through 1:1 age-, clinical stage-, and molecular subtype-matching. OS differences between the cases and controls were determined using Kaplan-Meier survival curve analyses. Here, 77.7 and 81.1% of the unmatched and matched cohort patients were aged <50 years, respectively. Of the matched neoadjuvant cases, 10 (15.6%) reached pathologic complete response after neoadjuvant chemotherapy, whereas 5 (13.5%) neoadjuvant cases succumbed during the study period. The neoadjuvant matched cases demonstrated a significantly poor OS with their adjuvant matched controls (P=0.044); nevertheless, the stratification analysis results demonstrated that the survival differences between the neoadjuvant and the adjuvant controls decreased after matching. Targeted therapy demonstrated the same OS benefits for both the neoadjuvant matched cases and adjuvant matched controls (P=1.000). This study provided matched case-control evidence for the feasibility of neoadjuvant chemotherapy combined with targeted therapy for patients with early-stage breast cancer with immediate breast reconstruction after mastectomy in a Taiwanese female population. D.A. Spandidos 2022-10-21 /pmc/articles/PMC9641822/ /pubmed/36420073 http://dx.doi.org/10.3892/ol.2022.13557 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Chia-Hua
Yang, Jie-Ru
Tsai, I-Chen
Hsu, Chiann-Yi
Yean, Lum Chih
Hung, Chih-Chiang
Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
title Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
title_full Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
title_fullStr Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
title_full_unstemmed Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
title_short Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
title_sort comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: a retrospective, matched case-control study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641822/
https://www.ncbi.nlm.nih.gov/pubmed/36420073
http://dx.doi.org/10.3892/ol.2022.13557
work_keys_str_mv AT liuchiahua comparisonofoverallsurvivalafterneoadjuvantandadjuvantchemotherapyinpatientswithearlybreastcancerwithimmediatebreastreconstructionaftermastectomyaretrospectivematchedcasecontrolstudy
AT yangjieru comparisonofoverallsurvivalafterneoadjuvantandadjuvantchemotherapyinpatientswithearlybreastcancerwithimmediatebreastreconstructionaftermastectomyaretrospectivematchedcasecontrolstudy
AT tsaiichen comparisonofoverallsurvivalafterneoadjuvantandadjuvantchemotherapyinpatientswithearlybreastcancerwithimmediatebreastreconstructionaftermastectomyaretrospectivematchedcasecontrolstudy
AT hsuchiannyi comparisonofoverallsurvivalafterneoadjuvantandadjuvantchemotherapyinpatientswithearlybreastcancerwithimmediatebreastreconstructionaftermastectomyaretrospectivematchedcasecontrolstudy
AT yeanlumchih comparisonofoverallsurvivalafterneoadjuvantandadjuvantchemotherapyinpatientswithearlybreastcancerwithimmediatebreastreconstructionaftermastectomyaretrospectivematchedcasecontrolstudy
AT hungchihchiang comparisonofoverallsurvivalafterneoadjuvantandadjuvantchemotherapyinpatientswithearlybreastcancerwithimmediatebreastreconstructionaftermastectomyaretrospectivematchedcasecontrolstudy